Telix Pharmaceuticals Limited (TLX)'s Commercial Progress Meets a Cautious Outlook [Yahoo! Finance]
Telix Pharmaceuticals Limited - American Depositary Shares (TLX)
Company Research
Source: Yahoo! Finance
Pharmaceuticals Limited (NASDAQ:TLX) with a Sector Perform rating and a price target of AUD17.00. The research firm notes that the company has successfully commercialized two diagnostic assets for prostate cancer and has substantial opportunities to expand indications. Although Telix Pharmaceuticals Limited (NASDAQ:TLX) has a diverse range of pipeline assets that it's working to commercialize, RBC expects earnings and free cash flow to remain essentially flat between fiscal years 2025 and 2027 as the company engages in R&D. Copyright: dolgachov / 123RF Stock Photo Earlier, on December 10, Telix Pharmaceuticals Limited (NASDAQ:TLX) announced a strategic clinical partnership with Varian to build applications integrating the company's theranostic offering with external beam radiation therapy (EBRT). With an aim to accelerate radiation oncology treatments, the collaboration will initially focus on using PSMA-PET imaging for individuals undergoing prostate cancer radiotherapy. Star
Show less
Read more
Impact Snapshot
Event Time:
TLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TLX alerts
High impacting Telix Pharmaceuticals Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TLX
News
- Shareholders of Telix Pharmaceuticals Ltd. Should Contact The Gross Law Firm Before January 9, 2026 to Discuss Your Rights – TLXGlobeNewswire
- Bronstein, Gewirtz & Grossman LLC Urges Telix Pharmaceuticals Limited Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire
- TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire
- Portnoy Law Firm Announces Class Action on Behalf of Telix Pharmaceuticals Limited InvestorsGlobeNewswire
- 21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing FailuresPR Newswire
TLX
Sec Filings
- 12/22/25 - Form 6-K
- 12/17/25 - Form 6-K
- 12/8/25 - Form 6-K
- TLX's page on the SEC website